1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,150 | 11,250 | 12.09. | |
| 11,100 | 11,300 | 11.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.08. | Biotech Stocks At 52-Week Highs - Bioventus, Travere Therapeutics, Odyssey Therapeutics, Charles River Laboratories Climb With Q2 Results, Aclaris Therapeutics | 922 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.Bioventus Inc. (BVS)Bioventus is a medical device... ► Artikel lesen | |
| 05.08. | Bioventus Inc. Q2 Profit Advances | 2 | RTTNews | ||
| 05.08. | Bioventus Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| BIOVENTUS Aktie jetzt für 0€ handeln | |||||
| 05.08. | Bioventus Non-GAAP EPS of $0.22 in-line, revenue of $153.2M misses by $2.44M | 1 | Seeking Alpha | ||
| 05.08. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.08. | Bioventus, Inc.: Bioventus Reports Second Quarter Financial Results | 279 | GlobeNewswire (Europe) | Q2 reported revenue of $153.2 million increased 4%Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted shareNon-GAAP earnings* of $0.22 per diluted... ► Artikel lesen | |
| 29.07. | Biotech Stocks At 52-Week Highs - Incyte Rises With Q2 Results, Pulse Biosciences, Shoulder Innovations, Bioventus, LB Pharmaceuticals | 801 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 28, 2026, driven by key catalysts including positive quarterly results.Incyte Corporation (INCY)Incyte is a... ► Artikel lesen | |
| 24.07. | Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect? | 1 | Zacks | ||
| 08.07. | Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know | 3 | Zacks | ||
| 07.07. | Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock? | 1 | Zacks | ||
| 23.06. | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | 528 | Xetra Newsboard | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| 04.06. | Bioventus Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Transcript: Bioventus Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 29.05. | Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 21.05. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.05. | Bioventus outlines 2026 adjusted EPS of $0.75-$0.79 while reaffirming $600M-$610M revenue | 1 | Seeking Alpha | ||
| 06.05. | Bioventus nach starkem Quartal: Gewinnprognose für 2026 angehoben | 5 | Investing.com Deutsch | ||
| 06.05. | Bioventus Q1 2026 slides: earnings beat drives guidance raise | 1 | Investing.com | ||
| 06.05. | Bioventus Non-GAAP EPS of $0.15 beats by $0.08, revenue of $132.1M beats by $2.2M | 2 | Seeking Alpha | ||
| 06.05. | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | 283 | GlobeNewswire (Europe) | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 4,982 | -0,64 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| BIOCRYST PHARMACEUTICALS | 7,006 | 0,00 % | TD Cowen startet Coverage für BioCryst mit Kaufempfehlung dank HAE-Medikament | ||
| CARDIOL THERAPEUTICS | 1,796 | +4,42 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission | TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,410 | -0,23 % | Arbutus Biopharma Corporation: Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified "Dutch Auction" Tender Offer | WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.09.2026 | Das Instrument 54Z FR0013399359 ENERGISME S.A. EO-,003 EQUITY wird cum Kapitalmassnahme gehandelt am 09.09.2026 und ex Kapitalmassnahme am 10.09.2026 The instrument 54Z FR0013399359 ENERGISME S.A. EO-... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,040 | 0,00 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| ALDEYRA | 1,160 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| DENALI THERAPEUTICS | 18,440 | +1,51 % | Mehr als 98% bleiben draußen: Warum Roche, Denali und NurExone neue Wege ins Nervensystem suchen | ||
| ABCELLERA BIOLOGICS | 8,910 | -5,31 % | AbCellera-Aktie mit +18% - neues Allzeithoch möglich? | Die AbCellera-Aktie hat zuletzt erneut einen kräftigen Kurssprung hingelegt. Am gestrigen Handelstag ging es um +17,81% nach oben. Damit setzt sich die außergewöhnliche Rallye fort: Seit dem lokalen... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 20,770 | -0,48 % | CSE Bulletin: Consolidation - Adaptogenics Health Corp. (ADPT) | Le 13 juillet/July 2026
Adaptogenics Health Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated share for four (4) pre-consolidated... ► Artikel lesen | |
| AC IMMUNE | 2,395 | +0,84 % | AC Immune SA: AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 | AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,157 | +0,43 % | Coherus Oncology, Inc.: Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights | - Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets - - Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,856 | +0,49 % | CytomX auf Wells-Fargo-Konferenz: Fokus auf EpCAM-Wirkstoff und solide Liquidität | ||
| CYBIN | 11,320 | +1,07 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
| AGENUS | 5,900 | -1,67 % | Agenus Inc.: Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 | Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have... ► Artikel lesen |
BIOVENTUS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,89 % bei einem Aktienkurs von 11,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVENTUS INC finden Sie auf Wallstreet Online.